SCHEMBL7427624

SCHEMBL7427624

OCCC([SiH3])(c1ccccc1)c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.37
CYP2C19 P33261 2/20 0.37
CYP1A2 P05177 2/20 0.37
CYP2C9 P11712 1/20 0.37
KIF11 P52732 4/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TSHR P16473 3/20 0.35
ALDH1A1 P00352 3/20 0.35
KCNN4 O15554 1/20 0.35
HIF1A Q16665 1/20 0.34
RECQL P46063 1/20 0.33
KDM4E B2RXH2 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33
ALOX15 P16050 1/20 0.33
MEN1 O00255 1/20 0.33
TTR P02766 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4660210 0.86 KIF11 (0.38) TDP1CYP2C19CYP1A2CYP2C9KIF11
SCHEMBL864054 0.76 KCNN4 (0.41) CYP2C19CYP1A2CYP2C9KIF11SMN1; SMN2
SCHEMBL19730614 0.75 TDP1 (0.40) TDP1CYP2C19CYP1A2CYP2C9KIF11
SCHEMBL29097001 0.75 TDP1 (0.40) TDP1CYP2C19CYP1A2CYP2C9KIF11
SCHEMBL913229 0.75 KIF11 (0.54) TDP1CYP2C19CYP1A2CYP2C9KIF11
SCHEMBL19614367 0.73 KCNN4 (0.48) TDP1CYP2C19CYP1A2CYP2C9KIF11
SCHEMBL301346 0.73 SMN1; SMN2 (0.55) CYP2C19CYP1A2CYP2C9KIF11SMN1; SMN2
SCHEMBL11212708 0.73 CYP2C19 (0.43) TDP1CYP2C19CYP1A2CYP2C9KIF11
SCHEMBL12727017 0.73 CYP1A2 (0.54) TDP1CYP2C19CYP1A2CYP2C9KIF11
SCHEMBL4194598 0.73 KIF11 (0.38) KIF11SMN1; SMN2TSHRALDH1A1KCNN4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020091142-A1 Alpha4beta1 and alpha4beta7 integrin inhibitors COOKE NIGEL GRAHAM (US) 2002-07-11 US disclosed
WO-2001068586-A2 α4β1 AND α4β7 INTEGRIN INHIBITORS NOVARTIS AG (CH) 2001-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091142-A1 Alpha4beta1 and alpha4beta7 integrin inhibitors ITGB1, ITGB4, ITGB7 TDP1 3566/4885CYP2C19 1781/4885CYP1A2 1922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.